The demand for erythema treatment in USA is projected to grow from USD 79 million in 2026 to USD 136.2 million by 2036, at a CAGR of 5.6%. Corticosteroids will dominate with a 35.0% market share, while topical will lead the route of administration segment with a 65.0% share.